Cabozantinib: A narrative drug review
| Autor: | Vivek K Srigadha, Kumar Prabhash, Vanita Noronha, Amit Joshi, Vijay M Patil, Nandini Menon, Ajay K Singh, Minit Shah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Cancer Research, Statistics, and Treatment, Vol 6, Iss 1, Pp 74-87 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2590-3233 2590-3225 |
| DOI: | 10.4103/crst.crst_9_23 |
| Popis: | Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively searched various websites, including the United States Food and Drug Administration, the European Medicine Agency Drug Manual, PubMed, Science Direct, and UpToDate using the search terms, “cabozantinib,” “renal cell carcinoma,” “hepatocellular carcinoma,” “differentiated thyroid cancer,” and “medullary thyroid cancer.” We shortlisted all the full-text articles published between 2011 and 2022. Out of a total of 788 manuscripts identified, we included 52. This review of cabozantinib details the pharmacodynamics, pharmacokinetics, clinical indications, adverse effects, safety, and the key research trials that investigated the use of cabozantinib. We have discussed the available clinical trial data and real-world outcomes, both with respect to the efficacy and safety of cabozantinib. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|